Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04629495
PHASE2

Rapamycin - Effects on Alzheimer's and Cognitive Health

Sponsor: The University of Texas Health Science Center at San Antonio

View on ClinicalTrials.gov

Summary

This study will evaluate the safety, tolerability, and feasibility of 12 month oral rapamycin treatment in older adults with amnestic mild cognitive impairment (aMCI) and early stage Alzheimer's disease (AD).

Official title: Rapamycin - Effects on Alzheimer's and Cognitive Health (REACH)

Key Details

Gender

All

Age Range

55 Years - 89 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2021-08-11

Completion Date

2026-03

Last Updated

2025-09-03

Healthy Volunteers

No

Interventions

DRUG

Rapamycin

RAPA will be administered orally 1mg daily

OTHER

Placebo

Placebo will be administered orally once daily

Locations (1)

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases

San Antonio, Texas, United States